Trypsin-based proteolysis cuts the ubiquitin or ubiquitin-like modifier while leaving two glycine residues attached to the substrate lysine. This produces the K-ε-GG tag on the resulting peptide rather than preserving the entire modifier. The remnant therefore converts a transient protein-modification event into a peptide-level signal that can be enriched and detected by mass spectrometry.
The tag remains covalently connected to the substrate lysine after digestion, marking the residue that carried the modifier. Its position within the peptide allows tandem mass spectrometry to assign the modified lysine and map its location in the parent protein. This site-level information is more specific than simply observing that the protein contains a modification.
A di-glycine profile can show changes in ubiquitination sites across proteins involved in degradation, signaling, DNA repair, and cell-cycle regulation. Comparing these profiles between cancer states or experimental conditions helps connect altered modification patterns with pathway activity. The resulting map can therefore expose regulatory changes that protein-level measurements alone may not localize to specific lysine residues.
A typical workflow digests the protein sample with trypsin, enriches peptides carrying the K-ε-GG remnant with anti-diGly antibodies, and analyzes the enriched fraction by liquid chromatography-tandem mass spectrometry. Chromatographic separation helps organize the peptide mixture, while tandem mass spectrometry supplies sequence and site information. Together, these steps produce a map of modified lysines.
Anti-diGly antibodies selectively capture peptides bearing the di-glycine remnant from the much larger pool of peptides produced by digestion. Enrichment concentrates modification-containing species before liquid chromatography-tandem mass spectrometry, making site mapping more focused. Without this selection step, the modified peptides would be analyzed alongside many unrelated digestion products, reducing the specificity of the profiling workflow.
Researchers can apply the approach when they need to compare ubiquitination patterns across tumor-associated conditions, treatment responses, or targeted-therapy experiments. The resulting site maps may highlight altered degradation pathways, signaling networks, DNA-repair processes, or cell-cycle regulation. These findings can support investigation of candidate biomarkers and potential drug targets without relying only on overall protein abundance.
Treatment-related differences in K-ε-GG peptide abundance indicate that modification patterns have changed at particular lysine sites or across associated proteins. Researchers can compare those shifts with pathways linked to degradation, signaling, DNA repair, or cell-cycle control to identify affected biological processes. Such comparisons help characterize the molecular response to targeted therapy and prioritize changes for further study.